ArticleCurrent microbiology2025
Carbapenem Resistant Serratia marcescens Harboring bla
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of Serratia marcescens as a significant healthcare-associated pathogen is compounded by its rising carbapenem resistance resulting in a critical global health challenge. This study is the first in Pakistan to comprehensively characterize the antimicrobial resistance patterns and molecular mechanisms of S. marcescens from clinical specimens. The S. marcescens isolates were obtained from clinical specimens collected at tertiary care hospitals in Lahore and Faisalabad, Pakistan, between October 2023 and September 2024. Isolates were identified using the Vitek-2 system and MALDI-TOF mass spectrometry. The disk diffusion assays, and broth microdilution method were used for antimicrobial susceptibility testing. The antimicrobial resistance determinants were amplified by PCR followed by sanger sequencing. The study revealed concerning resistance rates among S. marcescens isolates: 78% were resistant to third-generation cephalosporins, 52% to carbapenems, and 71.6% to fluoroquinolones. However, no isolates were found to be resistant to the tigecycline. The carbapenem resistance genes were distributed among carbapenem-resistant S. marcescens (CRSM) strains as follows: bla
Indexed as
Identifiers
40459633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.